Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Clinical Updates on Oral Minoxidil and Spironolactone for Androgenetic Alopecia

Description

The talk reviewed recent clinical updates on oral minoxidil and spironolactone for androgenetic alopecia, emphasizing emerging evidence for combination therapy, sublingual minoxidil, extended-release oral minoxidil, and practical dosing considerations. A retrospective study of 432 women found that oral spironolactone plus low-dose oral minoxidil was generally safe and well tolerated, with mostly mild adverse effects such as hypertrichosis, dizziness, edema, and palpitations; however, patients taking other blood-pressure-lowering medications or who were older had higher hypotension risk and need closer monitoring. The speaker also highlighted sublingual minoxidil as a promising approach that bypasses first-pass metabolism and may improve follicular bioavailability, with phase 3 trials showing dose-related increases in hair fiber diameter and evidence of conversion of miniaturized hairs toward terminal hairs, though studies remain limited by small samples and short follow-up. Extended-release oral minoxidil was presented as an important innovation in development for both men and women, designed to provide steadier drug levels and potentially reduce cardiac side effects compared with immediate-release dosing; the speaker noted a personal case of pericarditis even at 5 mg daily, underscoring caution with oral use. In the NYU retrospective study on low-dose oral minoxidil, improvement in hair density and diameter appeared within 3 to 6 months, plateaued around 6 to 12 months, and benefits were largely maintained thereafter, suggesting patients can be counseled that maximal response typically occurs within 1 to 2 years. Another study suggested morning dosing may yield better hair density outcomes than nighttime dosing, likely because hair follicle activity follows a circadian rhythm, though this finding is also retrospective and needs prospective confirmation.

View more

Conclusions

Combination oral spironolactone and low-dose oral minoxidil appears to be safe and generally well tolerated for women with androgenetic alopecia, with mostly mild adverse effects.
Patients taking additional blood-pressure-lowering medications need closer monitoring because the combination can increase hypotension-related symptoms and edema risk.
Simultaneous initiation of spironolactone and oral minoxidil may reduce hypertrichosis compared with sequential use.
Sublingual minoxidil shows dose-dependent increases in hair fiber diameter and may allow some reversal of follicular miniaturization.
Early studies suggest sublingual minoxidil can increase hair mass and density while potentially limiting hemodynamic side effects by bypassing first-pass metabolism.
Extended-release oral minoxidil is being developed to improve efficacy and maintain exposure above the hair-growth threshold while staying below the cardiac safety threshold.
The extended-release formulation may offer a promising non-hormonal oral option for both men and women with pattern hair loss, pending phase 3 confirmation and FDA approval.
Low-dose oral minoxidil tends to improve hair density and diameter early, usually within 3 to 6 months.
For low-dose oral minoxidil, hair density appears to plateau by about 6 to 12 months, while hair diameter may later decline over longer follow-up.
Daytime dosing of low-dose oral minoxidil may produce better hair-density outcomes than nighttime dosing, possibly reflecting circadian follicular activity.
Overall, current evidence supports oral minoxidil-based strategies as effective for androgenetic alopecia, but most data remain retrospective and prospective studies are still needed.

Dewey E, Salloum L, Gregoire S, McIntosh BA, Zhao V, Mostaghimi A. Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study. Journal of the American Academy of Dermatology.#10.1016/j.jaad.2026.02.003
Sublingual minoxidil increases fibre diameter in male androgenetic alopecia: a proxy for reversal of hair follicle miniaturization. Clinical and Experimental Dermatology. 2025. PMID: 39774750. DOI: 10.1093/ced/llaf012.#10.1093/ced/llaf012